Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

cLSC

Phase 1Biologic

UUniversity of California, Los Angeles

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Limbal Stem Cell DeficiencyActive, not recruiting

Limbal Stem Cell DeficiencyPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Limbal Stem Cell Deficiency

NCT03957954

Clinical

Trials by Indication[1]

Limbal Stem Cell Deficiency1 trial

Stem Cell Therapy for Limbal Stem Cell Deficiency

Active, not recruiting·UUniversity of California, Los Angeles·Phase 1·NCT03957954·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cLSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cLSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cLSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of California, Los Angeles

Related News